LABELS · d8b602aa-a61d-44db-acc7-46f3bc698b24

Yuflyma

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-07-15
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue YUFLYMA if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting YUFLYMA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products. SERIOUS INFECTIONS Patients treated with adalimumab products, including YUFLYMA, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue YUFLYMA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before YUFLYMA use and during therapy. Initiate treatment for latent TB prior to YUFLYMA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with YUFLYMA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with YUFLYMA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions ( 5.2 )]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 )].

Indications and usage: exact source text

1 INDICATIONS AND USAGE YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active p soriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis YUFLYMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUFLYMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUFLYMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUFLYMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUFLYMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUFLYMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUFLYMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUFLYMA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUFLYMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis YUFLYMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUFLYMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa YUFLYMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis YUFLYMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

Full extracted label fields

application numbers

BLA761219

boxed warning exact

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue YUFLYMA if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting YUFLYMA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products. SERIOUS INFECTIONS Patients treated with adalimumab products, including YUFLYMA, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue YUFLYMA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before YUFLYMA use and during therapy. Initiate treatment for latent TB prior to YUFLYMA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with YUFLYMA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with YUFLYMA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions ( 5.2 )]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 )].

brand names

Yuflyma

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=526d626f-8c9f-496c-b838-00a73bb36383

generic names

ADALIMUMAB-AATY

d8b602aa-a61d-44db-acc7-46f3bc698b24

indications and usage exact

1 INDICATIONS AND USAGE YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active p soriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis YUFLYMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUFLYMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUFLYMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUFLYMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUFLYMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUFLYMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUFLYMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUFLYMA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUFLYMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis YUFLYMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUFLYMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa YUFLYMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis YUFLYMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

indications and usage tables exact

is original packager

true

manufacturer names

CELLTRION USA, Inc.

matched search terms

tumor

package ndcs

72606-030-01
72606-030-02
72606-030-03
72606-030-04
72606-030-05
72606-030-06
72606-030-07
72606-030-08
72606-030-09
72606-030-10
72606-030-11
72606-030-12

product ndcs

72606-023
72606-030
72606-024
72606-046
72606-039
72606-063

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

RECENT MAJOR CHANGES Indications and Usage, Hidradenitis Suppurativa ( 1.8 ) 10/2025 Indications and Usage, Uveitis ( 1.9 ) 10/2025 Dosage and Administration, Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Uveitis ( 2.3 ) 10/2025 Dosage and Administration, Recommended Dosage in Hidradenitis Suppurativa ( 2.7 ) 10/2025 Warnings and Precautions, Autoimmunity ( 5.9 ) 10/2025

record type

complete_spl_indications_section_candidate

routes

rxcuis

797544
2639651
2639657
2639659
2639662
2639664
2639665
2639666
2639667
2668483
2668484
2668485

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 508
end exclusive: true
exact text: 1 INDICATIONS AND USAGE YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 0

current approval status

not_reconciled

duplicate text group

dup-012bccadd70ede9a68f2

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-794e8dacc66325666e74

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 82
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 32

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis .
kind
age
polarity
not_inferred
span
end
249
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
235

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 308
end exclusive: true
exact text: 1 INDICATIONS AND USAGE YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis .
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 659
end exclusive: true
exact text: mptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active p soriatic arthritis . ( 1.3 ) Reducing signs and s
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 109

current approval status

not_reconciled

duplicate text group

dup-1bed1a99c6f0a5deb097

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-1ece0feae85987e2d004

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

context exact
ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
448
end exclusive
true
exact text
2 years of age
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
434

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 459
end exclusive: true
exact text: ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 309

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 830
end exclusive: true
exact text: ately to severely active r heumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active p soriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 260

current approval status

not_reconciled

duplicate text group

dup-c5ef4a27147a7be357aa

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-3361231cd18c83643292

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 82
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 32

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with active p soriatic arthritis .
kind
age
polarity
not_inferred
span
end
595
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
581

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 630
end exclusive: true
exact text: ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active p soriatic arthritis .
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 460

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 921
end exclusive: true
exact text: ts 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active p soriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 431

current approval status

not_reconciled

duplicate text group

dup-9d306894423f4f8a133d

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-6e60f0b8737732cad130

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 82
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 32

qualifier mentions

context exact
( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
kind
age
polarity
not_inferred
span
end
684
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
670

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 721
end exclusive: true
exact text: ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 631

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1047
end exclusive: true
exact text: n of structural damage, and improving physical function in adult patients with active p soriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or we
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 522

current approval status

not_reconciled

duplicate text group

dup-cde094150873edaa8d2e

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-15284141f595edb0b809

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 82
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 32

qualifier mentions

context exact
eatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
798
end exclusive
true
exact text
adults
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
792
context exact
moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
821
end exclusive
true
exact text
pediatric patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
803
context exact
ely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
836
end exclusive
true
exact text
6 years of age
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
822

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 847
end exclusive: true
exact text: ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 722

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1136
end exclusive: true
exact text: signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chroni
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 648

current approval status

not_reconciled

duplicate text group

dup-8cef7d8a4e2b97ec074a

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-c17c2737354ca6d61c88

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

context exact
ment of moderately to severely active ulcerative colitis in adult patients.
kind
age
polarity
not_inferred
span
end
935
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
921

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 936
end exclusive: true
exact text: ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 848

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · limitation of use

application numbers

BLA761219

brand names

Yuflyma

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1277
end exclusive: true
exact text: nt of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 737

current approval status

not_reconciled

duplicate text group

dup-c59735926791452614db

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-13cc39e9975fc32d2df5

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1077
end exclusive: true
exact text: ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 937

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 8 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1477
end exclusive: true
exact text: y to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pedia
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 878

current approval status

not_reconciled

duplicate text group

dup-8dfdb8bbd9781c5bee73

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-d6aac31956dbde879622

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

context exact
Treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
kind
age
polarity
not_inferred
span
end
1105
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
1091

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1277
end exclusive: true
exact text: Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1078

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1581
end exclusive: true
exact text: Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis YUFLYMA is indicated for reduci
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1078

current approval status

not_reconciled

duplicate text group

dup-2c1f96e135fafc97b4fc

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-bc65907bc685864c7f02

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

context exact
of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
kind
age
polarity
not_inferred
span
end
1370
end exclusive
true
exact text
12 years of age
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
1355

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1381
end exclusive: true
exact text: ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1278

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1716
end exclusive: true
exact text: emic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis YUFLYMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical functi
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1182

current approval status

not_reconciled

duplicate text group

dup-d7bedc7bd4e68f7fb8ea

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-7cd30fec1a12086e054d

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

context exact
f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1467
end exclusive
true
exact text
adults
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
1461
context exact
tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1490
end exclusive
true
exact text
pediatric patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
1472
context exact
posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1505
end exclusive
true
exact text
2 years of age
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
1491

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1516
end exclusive: true
exact text: ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1382

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1724
end exclusive: true
exact text: hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis YUFLYMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in ad
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1317

current approval status

not_reconciled

duplicate text group

dup-a04dba797e2913d71e4b

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-0e24c0b67c75b7470075

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1524
end exclusive: true
exact text: ( 1.9 )
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1517

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1993
end exclusive: true
exact text: nitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis YUFLYMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUFLYMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUFLYMA is indicated for reducin
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1325

current approval status

not_reconciled

duplicate text group

dup-d87cb1c4c3dcda76bedb

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-0816032894bc9836e66d

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 1570
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1558

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
kind
age
polarity
not_inferred
span
end
1736
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
1722

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1793
end exclusive: true
exact text: 1.1 Rheumatoid Arthritis YUFLYMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1525

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 13 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2126
end exclusive: true
exact text: symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUFLYMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUFLYMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and olde
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1594

current approval status

not_reconciled

duplicate text group

dup-a0718e647d82e1abee7b

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-8725a9d93e119416f823

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

context exact
YUFLYMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
kind
biomarker
polarity
not_inferred
span
end
1886
end exclusive
true
exact text
methotrexate or other non-biologic disease-
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
1843
context exact
YUFLYMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
kind
regimen
polarity
not_inferred
span
end
1925
end exclusive
true
exact text
in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs)
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
1823

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1926
end exclusive: true
exact text: YUFLYMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1794

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2328
end exclusive: true
exact text: patients with moderately to severely active rheumatoid arthritis. YUFLYMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUFLYMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUFLYMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUFLYMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and impro
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1727

current approval status

not_reconciled

duplicate text group

dup-425370d5dc00fb0f2ea2

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-39a8a8b47adb1230a2af

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 1981
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1969

qualifier mentions

context exact
ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
2117
end exclusive
true
exact text
2 years of age
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2103

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2128
end exclusive: true
exact text: 1.2 Juvenile Idiopathic Arthritis YUFLYMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1927

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 15 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2391
end exclusive: true
exact text: 2 Juvenile Idiopathic Arthritis YUFLYMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUFLYMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUFLYMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1929

current approval status

not_reconciled

duplicate text group

dup-2411c8fab1b3a087d43c

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-6f1fb8b0741ce391e2d9

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

context exact
YUFLYMA can be used alone or in combination with methotrexate.
kind
biomarker
polarity
not_inferred
span
end
2190
end exclusive
true
exact text
methotrexate
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2178
context exact
YUFLYMA can be used alone or in combination with methotrexate.
kind
regimen
polarity
not_inferred
span
end
2190
end exclusive
true
exact text
in combination with methotrexate
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2158

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2191
end exclusive: true
exact text: YUFLYMA can be used alone or in combination with methotrexate.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2129

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 16 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2601
end exclusive: true
exact text: ng signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUFLYMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUFLYMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUFLYMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUFLYMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondyli
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 1992

current approval status

not_reconciled

duplicate text group

dup-858a434fba72dafa53dc

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-cba6a4d49475095d4824

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 2236
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2224

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
kind
age
polarity
not_inferred
span
end
2368
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2354

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2401
end exclusive: true
exact text: 1.3 Psoriatic Arthritis YUFLYMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2192

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 17 · unclassified context

application numbers

BLA761219

brand names

Yuflyma

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2671
end exclusive: true
exact text: tic Arthritis YUFLYMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUFLYMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUFLYMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUFLYMA is indicated for the treatment of mod
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2202

current approval status

not_reconciled

duplicate text group

dup-01e0bd727a785c79ff10

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-4adfbf0dabdc5cfc7bc6

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

context exact
YUFLYMA can be used alone or in combination with non-biologic DMARDs.
kind
regimen
polarity
not_inferred
span
end
2470
end exclusive
true
exact text
in combination with non-biologic DMARDs
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2431

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2471
end exclusive: true
exact text: YUFLYMA can be used alone or in combination with non-biologic DMARDs.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2402

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 18 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2805
end exclusive: true
exact text: hibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUFLYMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUFLYMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUFLYMA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUFLYMA i
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2272

current approval status

not_reconciled

duplicate text group

dup-32f27dde3e28a4593685

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-ca8e4285e9cb6da6a7ff

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 2519
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2507

qualifier mentions

context exact
tis YUFLYMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
kind
age
polarity
not_inferred
span
end
2569
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2555

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2605
end exclusive: true
exact text: 1.4 Ankylosing Spondylitis YUFLYMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2472

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 19 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2972
end exclusive: true
exact text: YMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUFLYMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUFLYMA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUFLYMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has no
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2406

current approval status

not_reconciled

duplicate text group

dup-66553d41ae8dff1a53e3

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-a50ec5006445990993a2

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 2646
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2634

qualifier mentions

context exact
eatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2723
end exclusive
true
exact text
adults
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2717
context exact
moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2746
end exclusive
true
exact text
pediatric patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2728
context exact
ely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2761
end exclusive
true
exact text
6 years of age
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2747

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2772
end exclusive: true
exact text: 1.5 Crohn's Disease YUFLYMA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2606

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 20 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3105
end exclusive: true
exact text: h active ankylosing spondylitis. 1.5 Crohn's Disease YUFLYMA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUFLYMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Pla
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2573

current approval status

not_reconciled

duplicate text group

dup-cd23d4b2a73a2e1cc4ef

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-1f42625205079364e0df

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 2816
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2804

qualifier mentions

context exact
ment of moderately to severely active ulcerative colitis in adult patients.
kind
age
polarity
not_inferred
span
end
2904
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
2890

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2905
end exclusive: true
exact text: 1.6 Ulcerative Colitis YUFLYMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2773

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 21 · limitation of use

application numbers

BLA761219

brand names

Yuflyma

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 3297
end exclusive: true
exact text: disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUFLYMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis YUFLYMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2706

current approval status

not_reconciled

duplicate text group

dup-ec684dc89de57221746a

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-7eb191de7eb52721397b

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3097
end exclusive: true
exact text: Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] .
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2906

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 22 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3547
end exclusive: true
exact text: tients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis YUFLYMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUFLYMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa YU
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 2898

current approval status

not_reconciled

duplicate text group

dup-7d441a9cb81cc1c192b7

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-432a824631d7e85bf284

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 3139
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3127

qualifier mentions

context exact
Plaque Psoriasis YUFLYMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
kind
age
polarity
not_inferred
span
end
3175
end exclusive
true
exact text
adult patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
3161

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3347
end exclusive: true
exact text: 1.7 Plaque Psoriasis YUFLYMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3098

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 23 · risk or warning

application numbers

BLA761219

brand names

Yuflyma

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 3715
end exclusive: true
exact text: treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUFLYMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa YUFLYMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis YUFLYMA is indicated for the trea
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3148

current approval status

not_reconciled

duplicate text group

dup-7c65ab08ff390971d423

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-d4161a70b08cff193149

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3515
end exclusive: true
exact text: YUFLYMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] .
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3348

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 24 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3837
end exclusive: true
exact text: are medically less appropriate. YUFLYMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa YUFLYMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis YUFLYMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3316

current approval status

not_reconciled

duplicate text group

dup-d9a81305e81282593c64

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-01ff9000f5cb02ece2e1

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 3565
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3553

qualifier mentions

context exact
of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
kind
age
polarity
not_inferred
span
end
3658
end exclusive
true
exact text
12 years of age
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
3643

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3669
end exclusive: true
exact text: 1.8 Hidradenitis Suppurativa YUFLYMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3516

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 25 · positive indication candidate

application numbers

BLA761219

brand names

Yuflyma

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3837
end exclusive: true
exact text: sician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa YUFLYMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis YUFLYMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3470

current approval status

not_reconciled

duplicate text group

dup-784e2a2637d2fc66a2b3

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-AATY

ind-span-57f9ee762e802f3e003d

label id

d8b602aa-a61d-44db-acc7-46f3bc698b24

positive predicate support span

end: 3702
end exclusive: true
exact text: is indicated
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3690

qualifier mentions

context exact
f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
3788
end exclusive
true
exact text
adults
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
3782
context exact
tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
3811
end exclusive
true
exact text
pediatric patients
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
3793
context exact
posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
3826
end exclusive
true
exact text
2 years of age
label id
d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start
3812

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3837
end exclusive: true
exact text: 1.9 Uveitis YUFLYMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
label id: d8b602aa-a61d-44db-acc7-46f3bc698b24
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: edffd83be6b4dd3d401a393de0aae2dc487518b13afad734cd360314d68141df
start: 3670

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d8b602aa-a61d-44db-acc7-46f3bc698b24%22

spl effective date

2026-07-15

spl set id

526d626f-8c9f-496c-b838-00a73bb36383

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice